Core Viewpoint - Shenzhen Hanno Medical Technology Co., Ltd. is the first domestic company to achieve the localization of Extracorporeal Membrane Oxygenation (ECMO) systems and is now under scrutiny for compliance and operational sustainability as it aims to become the "first domestic ECMO stock" [1] Group 1: Company Overview - Hanno Medical was established in May 2018 and focuses on high-end medical device development in the field of extracorporeal life support, having overcome key technologies in ECMO system monitoring, blood pumps, membranes, and tubing consumables [1] - The company’s core product, Lifemotion® ECMO system, received approval from the National Medical Products Administration in January 2023, marking it as the first domestically approved ECMO device and consumable package [1] - Hanno Medical has completed 10 rounds of financing since its inception, attracting notable investors such as Daotong Investment and Mindray Medical, indicating strong capital recognition of its technological barriers and industry prospects [2] Group 2: Financial Performance - The company has shown a typical "increasing revenue without increasing profit" pattern, with revenue of 0 in 2022 due to the core product not being commercially sold, followed by revenues of 29.83 million in 2023 and projected growth to 49.31 million in 2024 [2] - Net profits have been under pressure, with losses of 64.79 million, 341 million, and 183 million from 2022 to 2024, totaling significant cumulative losses [2] - The company’s asset-liability ratio increased from 31.96% in 2022 to 72.36% in the first half of 2025, significantly exceeding the industry average of approximately 23% [4] Group 3: Research and Development - Hanno Medical has invested over 380 million in R&D from 2022 to 2024, with nearly 52 million in the first half of 2025, reflecting the high R&D demands of the ECMO industry [3] - The company employs 194 staff, with over 30% being R&D personnel, which exceeds the minimum requirement of 10% for high-tech enterprises on the Sci-Tech Innovation Board [3] - The company’s revenue is heavily reliant on the ECMO system, with derivative products like ECPR and CPS still in the early stages of commercialization and not yet contributing to revenue [3] Group 4: Regulatory and Market Implications - The recent inclusion in the on-site inspection list by the China Securities Association indicates that Hanno Medical will face comprehensive scrutiny regarding financial data authenticity, internal control integrity, and operational sustainability [4] - Successful navigation of this inspection could provide a compliance model for similar unprofitable hard-tech companies on the Sci-Tech Innovation Board, drawing significant market attention [4]

Core Insights - Shenzhen Hanno Medical Technology Co., Ltd. has submitted its application for listing on the Sci-Tech Innovation Board, aiming to raise 1.06 billion yuan for R&D, production, marketing, and working capital [1] - The company is one of the few globally to have a complete layout of ECMO devices and consumables, reflecting the Sci-Tech Innovation Board's support for unprofitable hard tech enterprises [1] Financial Performance - Hanno Medical's revenue is projected to grow from 29.83 million yuan in 2023 to 49.31 million yuan in 2024, with 37.36 million yuan achieved in the first half of 2025 [1] - The company's losses are narrowing, decreasing from 341 million yuan in 2023 to 82.27 million yuan in the first half of 2025 [1] Innovation and Technology - The company has developed seven core technologies and holds 38 invention patents, establishing a strong patent barrier [2] - The Lifemotion® ECMO system was approved for market entry in 2023, breaking the long-standing technological monopoly of countries like the US, Germany, and Italy [2] International Expansion - Hanno Medical's products are now used in over 140 hospitals across China and have achieved market entry in Brazil and South Africa [3] - The receipt of the EU CE MDR certification signifies that the quality and effectiveness of the company's high-end medical equipment meet international standards [3] Market Potential - The ECMO market in China is expected to grow from 960 million yuan in 2024 to 3.71 billion yuan by 2030, with a compound annual growth rate of 25.2% [4] - The global ECMO market is projected to reach 5.8 billion USD by 2035, highlighting the increasing demand for stable suppliers amid a fragile global supply chain [4] Business Model - Hanno Medical employs a "device-first, consumable-driven" business model, leading the domestic market for new ECMO devices due to performance and cost advantages [4] - The continuous consumption of high-value consumables ensures predictable cash flow, with plans to replicate this model in international markets [4]